Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Notes Payables (2016 - 2017)

Moleculin Biotech's Notes Payables history spans 2 years, with the latest figure at $108000.0 for Q1 2017.

  • Quarterly results put Notes Payables at $108000.0 for Q1 2017, down 82.44% from a year ago — trailing twelve months through Mar 2017 was $108000.0 (down 82.44% YoY), and the annual figure for FY2016 was $296000.0, changed.
  • Notes Payables for Q1 2017 was $108000.0 at Moleculin Biotech, down from $296000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $615000.0 in Q1 2016 to a low of $108000.0 in Q1 2017.